Continuation of gefitinib plus chemotherapy prolongs progression-free survival in advanced non-small cell lung cancer patients who get acquired resistance to gefitinib without T790M mutations

BACKGROUND: Aimed to identify the benefit population from continuation of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), this study investigated the efficacy of continuation of EGFR-TKIs plus chemotherapy beyond the response evaluation criteria in solid tumors-progressive d...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Thorac Dis
Autors principals: Ding, Ting, Zhou, Fei, Chen, Xiaoxia, Zhang, Shijia, Liu, Yinan, Sun, Hui, Ren, Shengxiang, Li, Xuefei, Zhao, Chao, Wang, Heyong, Zhou, Caicun
Format: Artigo
Idioma:Inglês
Publicat: AME Publishing Company 2017
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5708402/
https://ncbi.nlm.nih.gov/pubmed/29221264
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jtd.2017.07.107
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars